FRAG 176-191

• β₃-Adrenergic Receptor (β₃-AR) Pathway: Preclinical data indicate the fragment may increase expression or sensitivity of β₃-adrenergic receptors in adipocytes and skeletal muscle. This leads to elevated intracellular cAMP, activation of protein kinase A (PKA), phosphorylation of hormone-sensitive lipase (HSL), and subsequent triglyceride breakdown. Enhanced thermogenesis and fatty acid oxidation have also been observed in some models.
  academic.oup.com
• Direct Effects on Lipid Enzymes: It has been associated with stimulation of lipolytic activity and suppression of enzymes involved in fat synthesis (e.g., acetyl-CoA carboxylase), resulting in a net reduction in fat accumulation.
• Independence from GH/IGF-1 Axis: The peptide does not appear to bind significantly to the full GH receptor or stimulate IGF-1 production, differentiating its profile from native hGH in research settings.

These mechanisms have been examined mainly in obese rodent models (e.g., ob/ob mice, Zucker rats) and ex vivo adipose tissue, where chronic administration was linked to reduced body weight gain, increased fat oxidation, and altered lipid profiles without major disruptions to glucose homeostasis in the tested systems.

• Chronic treatment with the lipolytic fragment in obese mice reduced body weight, body fat mass, and increased lipolytic sensitivity in adipose tissue. Effects were associated with changes in β₃-AR expression.
  pubmed.ncbi.nlm.nih.gov
• Early studies showed the C-terminal hGH fragment stimulated lipolysis and inhibited lipogenesis in isolated adipose tissue from rodents and humans, with reduced lipogenic activity observed after oral administration in some models.
  tidelabs.co.uk
• Increased fat oxidation and reduced weight gain were reported in genetically obese animal models, independent of major IGF-1 changes.

Human Clinical Research (AOD-9604 Analog): Approximately 900 participants were involved across several Phase I and II trials. The compound was generally well-tolerated, with no significant effects on IGF-1 levels, glucose metabolism, insulin sensitivity, or immunogenicity. Some earlier trials reported modest body weight reductions (e.g., ~2.6 kg vs. ~0.8 kg placebo in one 12-week study at 1 mg/day), but larger Phase IIb trials incorporating diet and exercise did not consistently show statistically significant superiority over placebo for weight loss. Development as a pharmaceutical was discontinued after the pivotal trial.